Gene expression and immunohistochemical analyses identify SOX2 as major risk factor for overall survival and relapse in Ewing sarcoma patients

BACKGROUND: Up to 30–40% of Ewing sarcoma (EwS) patients with non-metastatic disease develop local or metastatic relapse within a time span of 2–10 years. This is in part caused by the absence of prognostic biomarkers that can identify high-risk patients and thus assign them to risk-adapted monitori...

Descripción completa

Detalles Bibliográficos
Autores principales: Sannino, Giuseppina, Marchetto, Aruna, Ranft, Andreas, Jabar, Susanne, Zacherl, Constanze, Alba-Rubio, Rebeca, Stein, Stefanie, Wehweck, Fabienne S., Kiran, Merve M., Hölting, Tilman L.B., Musa, Julian, Romero-Pérez, Laura, Cidre-Aranaz, Florencia, Knott, Maximilian M.L., Li, Jing, Jürgens, Heribert, Sastre, Ana, Alonso, Javier, Da Silveira, Willian, Hardiman, Gary, Gerke, Julia S., Orth, Martin F., Hartmann, Wolfgang, Kirchner, Thomas, Ohmura, Shunya, Dirksen, Uta, Grünewald, Thomas G.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796576/
https://www.ncbi.nlm.nih.gov/pubmed/31427232
http://dx.doi.org/10.1016/j.ebiom.2019.08.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796576/
https://www.ncbi.nlm.nih.gov/pubmed/31427232
http://dx.doi.org/10.1016/j.ebiom.2019.08.002

Ejemplares similares